Sexual Wellness Compliance & Marketing Claims Practice Toolkit

Navigating patient marketing for sexual wellness requires understanding the dual oversight of federal and state bodies. The Federal Trade Commission (FTC) regulates advertising claims, requiring all clinical assertions to be truthful, non-misleading, and backed by competent and reliable scientific evidence. Simultaneously, the Food and Drug Administration (FDA) regulates the clearance, approval, and intended use of medical supplies, hardware, and biologics.

Clinics offering regenerative or sexual health procedures must distinguish between device clearances and procedure indications. Marketing an FDA-cleared device for an unapproved clinical outcome without explicit disclosure can trigger regulatory scrutiny. Practices should review their general equipment platforms under /technologies to ensure marketing descriptions reflect exact manufacturer clearances rather than non-substantiated clinical outcomes.

Sexual wellness service lines frequently utilize a combination of autologous biologics, acoustic wave therapies, and energy-based devices. It is crucial to maintain strict boundaries in public marketing regarding what these modalities achieve.

When promoting platelet-rich plasma (PRP) or cellular therapies, marketing materials must avoid terms like 'cure,' 'reversal,' or guaranteed restoration of function. For autologous preparations, clinics should focus descriptions on the biological process rather than promising specific anatomical changes. Review your clinic's biological protocols via /biologics to verify that patient intake materials accurately define off-label applications where applicable.

Digital marketing assets—including landing pages, paid advertisements, and social media video content—are subject to the same regulatory standards as traditional media. Testimonials and before-and-after statements must represent typical patient experiences rather than extraordinary outcomes, or include clear, non-buried disclaimers.

Common compliance red flags in digital content include:

• Absolute outcome claims (e.g., '100% success rate' or 'permanent solution')
• Using FDA logos in a manner that implies agency endorsement of the practice
• Conflating device clearance with proof of clinical efficacy for off-label uses
• Omitting risk factors, side effects, or procedure limitations in promotional videos

Compliance extends beyond advertising into the consultation room. Informed consent documentation must clearly outline whether a procedure involves off-label device use, the experimental nature of certain biologic applications, and reasonable expectations of efficacy.

Practices integrating specialized care pathways should ensure intake staff and patient coordinators do not deliver non-compliant 'sales pitches.' Integrating compliant communication structures into your clinical workflow helps protect the practice while maintaining professional transparency across all medical /specialties.

Unlicensed administrative staff and patient care coordinators are frequent sources of inadvertent marketing violations. When handling inbound inquiries, staff must adhere to standardized scripts that do not diagnose, guarantee results, or misrepresent medical therapies.

Routine internal audits should evaluate phone recordings, chat transcripts, and email responses to verify that staff members direct clinical questions to treating physicians and accurately represent treatment limitations.